Renaissance Technologies LLC Has $14.43 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Renaissance Technologies LLC reduced its stake in Glaukos Co. (NYSE:GKOS) by 22.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 121,892 shares of the medical instruments supplier’s stock after selling 36,100 shares during the period. Renaissance Technologies LLC owned approximately 0.24% of Glaukos worth $14,426,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of GKOS. Vanguard Group Inc. grew its position in Glaukos by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock valued at $500,576,000 after acquiring an additional 72,159 shares during the period. Brown Capital Management LLC grew its holdings in shares of Glaukos by 3.4% in the 4th quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier’s stock worth $214,448,000 after purchasing an additional 89,420 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Glaukos by 3.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock worth $73,412,000 after purchasing an additional 31,213 shares in the last quarter. Primecap Management Co. CA lifted its holdings in Glaukos by 23.7% during the 4th quarter. Primecap Management Co. CA now owns 790,035 shares of the medical instruments supplier’s stock valued at $62,800,000 after purchasing an additional 151,415 shares during the last quarter. Finally, Iron Triangle Partners LP boosted its position in Glaukos by 75.6% in the first quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock valued at $40,500,000 after buying an additional 184,919 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Aimee S. Weisner sold 25,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the transaction, the director now directly owns 30,119 shares in the company, valued at approximately $3,614,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Aimee S. Weisner sold 25,000 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total value of $3,000,000.00. Following the completion of the transaction, the director now owns 30,119 shares of the company’s stock, valued at approximately $3,614,280. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,225,345.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,500 shares of company stock worth $5,099,000. Insiders own 6.40% of the company’s stock.

Glaukos Stock Down 1.8 %

Shares of NYSE GKOS opened at $127.78 on Friday. Glaukos Co. has a 1 year low of $59.22 and a 1 year high of $136.60. The firm’s 50-day moving average is $124.89 and its 200-day moving average is $111.54. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $6.44 billion, a PE ratio of -44.37 and a beta of 1.03.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The firm had revenue of $95.70 million during the quarter, compared to analyst estimates of $88.86 million. During the same quarter in the previous year, the business earned ($0.55) EPS. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. Equities analysts expect that Glaukos Co. will post -2.18 EPS for the current year.

Analysts Set New Price Targets

GKOS has been the subject of several recent analyst reports. Needham & Company LLC raised their price objective on shares of Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Citigroup downgraded Glaukos from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $130.00 to $132.00 in a research report on Wednesday, July 10th. Truist Financial restated a “buy” rating and set a $145.00 target price (up previously from $141.00) on shares of Glaukos in a report on Thursday, August 1st. Piper Sandler lifted their price target on Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, BTIG Research upped their price target on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $129.82.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.